1. <sub id="imcdt"><listing id="imcdt"></listing></sub>
      <form id="imcdt"><em id="imcdt"><span id="imcdt"></span></em></form>
      <wbr id="imcdt"></wbr>
      Welcome to HitGen

      Available now!
      Whitepaper:Advancing Drug Discovery through DNA Encoded Library Technology

      Read more

      OpenDEL?: Making DNA-Encoded Library Screening Broadly Available

      Read more

      Advancing Innovative Drug Discovery

      Read more

      Drug discovery, it's in our DNA.

      Read more

      Enable Innovative Drug Discovery with DEL, FBDD and SBDD

      Read more

      Capabilities & Services

      Enabling Innovative Drug Discovery with Advanced Technologies

      • DNA-encoded Library
        DNA-encoded Library
      • Fragment-based Drug Discovery
        FBDD/SBDD
      • Chemistry
        Chemistry
      • Bioscience
        Bioscience
      • Computational Sciences and Informatics
        Computational Sciences and Informatics
      • Structural Biology
        Structural Biology
      • Pre-clinical Studies
        Pre-clinical Studies
      • Clinical Development
        Clinical Development

      Therapeutic Areas

      Integrated One-stop Drug Discovery Platform   Accelerating Project with High Efficiency

      • Oncology and Immuno-oncology
        Oncology and Immuno-oncology
      • Inflammatory and Autoimmune Diseases
        Inflammatory and Autoimmune Diseases
      • Ophthalmology
        Ophthalmology
      • Infectious Diseases
        Infectious Diseases
      • Metabolic Diseases
        Metabolic Diseases
      • Cardiovascular Diseases
        Cardiovascular Diseases
      HitGen Inc. is a rapidly developing biotech company
      The discovery and development of novel medicines and agrochemicals
      >1 Trillion

      DNA encoded compounds

      >6,000

      novel drug/target complex structures for FBDD/SBDD

      About Us

      HitGen Inc. is a biotech company headquartered in Chengdu, China, with subsidiaries in Cambridge, UK and Houston, USA. It became a publicly listed company in Shanghai Stock Exchange in April 2020 (ticker code 688222.SH).  HitGen has established a drug discovery research platform for small molecules and nucleic acid drug centered on the design, synthesis and screening of DNA encoded chemical libraries (DELs), fragment-based drug discovery (FBDD) and structure-based drug design (SBDD) technologies. HitGen's DELs currently contains more than 1 trillion novel, diverse, drug-like small molecules and macrocyclic compounds. These compounds are members of DELs synthesized from many thousands of distinct chemical scaffolds, designed with tractable chemistry, and have yielded proven results for the discovery of small molecule leads against precedented and unprecedented classes of biological targets.

       

      Through its acquisition of Cambridge UK based Vernalis R&D Ltd before the end of 2020, a leader in FBDD/SBDD, HitGen now has a research team of over 500 scientists and offers a full set of research capabilities from recombinant protein expression and purification, structural biology, assay development, screening, DEL synthesis, nucleic acid and small molecule chemical synthesis, computational and medicinal chemistry, biochemistry and biophysics, cell biology, in vivo pharmacology, DMPK, CMC, etc., to enable drug discovery research from target gene to IND filing.

       

      HitGen RNA therapeutics R&D platform includes key capabilities such as bioinformatics, organic chemistry and medicinal chemistry,RNA biology, molecular biology and cell biology, translational research and clinical research. The platform not only provides high quality services to support internal and external RNA therapeutics R&D projects, but also carries out siRNA sequence design, siRNA parallel synthesis and chemical modification/conjugation, mRNA and protein knock-down assays in both engineered cell lines and primary cell lines, stability test, off-target assessment, bio-distribution and other relate in vitro/in vivo assays for activity and toxicity study, etc. HitGen has also established its own pipelines in early stages to discover novel RNA therapeutics, aiming for providing new treatment for unmet medical needs in oncology and immunology.

       

      HitGen operates a flexible business model, ranging from a single capability-based fee for services (FFS,e.g., protein expression and purification, structural biology, bioinformatics, computational chemistry, medicinal chemistry, nucleic and organic chemistry, analytical chemistry, biophysics, PK, PD, etc.), DEL screening, DEL design, synthesis and characterization, integrated drug discovery projects, risk sharing projects, collaborative ventures to program out-licensing. HitGen has approximately 20 in-house drug discovery programs at different stages of research & development. At present, 4 programs have obtained IND approvals by NMPA and entered into clinical trials. HitGen is collaborating with pharmaceutical, biotech and chemical companies, foundations and research institutes in North America, Europe, Asia, Africa and Australia to enable the discovery and development of novel medicines and agrochemicals.


      For more information, please call +86-28-85197385, +1-508-840-9646 or visit www.anyaplana.com.

      For media inquiries: media@hitgen.com

      For investor inquiries: investors@hitgen.com  

      For business development: bd@hitgen.com  


      Read More

      Collaboration Partners

      Latest News

      • 05 May 2022

        Infographic | HitGen FY2021 Annual Report

        Infographic | HitGen FY2021 Annual Report
        + Read More
      • 19 April 2022

        HitGen and the PACS1 Syndrome Research Foundation announce an agreement to discover ligands that address issues related to the mutated PACS1 gene product

        CHENGDU, China, April 19, 2022 – HitGen Pharmaceuticals Inc. and the PACS1 Syndrome Research Foundation announce an agreement focused on the application of HitGen’s DNA-encoded library (DEL) technology to identify ligands that could selectively bind to the mutated PACS1 Protein and therefore serve as a treatment or a cure for patients with PACS1 Syndrome.
        + Read More
      • 06 April 2022

        HitGen and UPPTHERA Extend PROTAC Research Collaboration after Hit Finding Success on Undruggable Targets

        CHENGDU, China, April 6, 2022 – HitGen Inc. (“HitGen”), a Shanghai Stock Exchange STAR-listed company, today announced that the company has successfully completed the multiple-target drug discovery research projects with UPPTHERA, a Korean pharmaceutical company aiming for new drug development employing “Protein Degradation Technology”. During the collaboration, multiple undisclosed targets were screened against HitGen’s proprietary over 1 trillion DNA-encoded libraries (DELs). The majority of the targets have resulted in confirmed hits, which have high potential for PROTAC development. Now the two parties are extending the collaboration on further development of these projects and additional challenging targets.
        + Read More
      Investors

      Latest Announcements,
      Financial News and Stock Information

      Read More

      Questions?

      For more details on how we can advance your innovative drug discovery projects
      By submitting your information, you acknowledge having received, read and understood our Privacy Notice as made available above.

      We use cookies to provide a better web experience.
      By using our site, you acknowledge our use of cookies and please read our Cookie Notice for More information

      97资源
        1. <sub id="imcdt"><listing id="imcdt"></listing></sub>
          <form id="imcdt"><em id="imcdt"><span id="imcdt"></span></em></form>
          <wbr id="imcdt"></wbr>